Saturday, March 6, 2021
Home Latest Pharma-News WHO announces updates on new molecular assays for the diagnosis of TB...

WHO announces updates on new molecular assays for the diagnosis of TB and drug resistance

February 17, 2021: “Significant advances to the diagnosis of tuberculosis (TB) and drug resistance in adults, adolescents and children are expected, following key updates on new molecular assays, announced by the World Health Organization (WHO) in a Rapid Communication released.

Diagnosis of TB and drug-resistant TB remains a challenge with a third of people with TB and more than a half of people with drug-resistant TB not receiving quality diagnosis and care globally.

- Advertisement -

To address this challenge, WHO convened a meeting of a Guideline Development Group in December 2020, to update WHO policies on molecular assays used for the diagnosis of TB and drug resistance.

Highlights from the evidence reviewed and presented in the Rapid Communication show high diagnostic accuracy for 3 new classes of technologies:

  1. Moderate complexity automated Nucleic Acid Amplification Tests (NAATs), for detection of TB and resistance to rifampicin and isoniazid;
  2. Low complexity automated NAATs for detection of resistance to isoniazid and second-line anti-TB agents;
  3. High complexity hybridization-based NAATs for detection of resistance to pyrazinamide.

The Rapid Communication has been released in advance of updated WHO guidelines expected later in 2021, to inform national TB programmes and other stakeholders about these new developments for the diagnosis of TB and drug resistance in order to allow for rapid transition and planning at country level.

“The diagnostic options for people with TB and drug-resistant TB are increasing thanks to the engagement of manufacturers and to research that is generating new evidence.

Ensuring that everyone can obtain a rapid and accurate diagnosis, followed by treatment according to the latest WHO guidelines, will save lives and reduce suffering” said Dr Tereza Kasaeva, Director of the WHO Global TB Programme.

“We ask for renewed political commitment and stakeholder support in ensuring these updates are rapidly implemented.”

https://www.who.int/news/item/17-02-2021-who-announces-updates-on-new-molecular-assays-for-the-diagnosis-of-tuberculosis-(tb)-and-drug-resistance

LEAVE A REPLY

Please enter your comment!
Please enter your name here

ten + 18 =

Most Popular

FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

March 05, 2021: "The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by...

EMA issues advice on Lilly’s bamlanivimab with etesevimab for confirmed COVID-19 in EU

March 5, 2021: "Eli Lilly and Company announced that the EMA Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion...

MHRA says modified COVID-19 vaccines for variants to be fast-tracked

March 04, 2021: "Authorised COVID-19 vaccines that are modified in response to new variants will not need a brand new approval or “lengthy” clinical studies,...

Co-WIN Covid-19 vaccine registration prosess

Co-WIN Covid-19 vaccine registration: The registrations for the Covid-19 vaccine registration opened from 9 AM on March 1 till 3 PM every...